Expert Opinion – Professor Josef Vormoor and Dr Olaf Heidenreich

Being told your child has cancer is every parent’s worst nightmare. But every year, around 1500 families are given this devastating news. And while survival rates for childhood cancers have improved significantly, around 300 children still lose their lives to cancer each year.

That’s 300 too many and we’re determined to bring that number down to zero. To do that, we need to have the brightest and most committed minds on board. So, in April this year, we were pleased to support an application for funding from Professor Josef Vormoor and Dr Olaf Heidenreich, both at the Northern Institute for Cancer Research in Newcastle.

Professor Josef Vormoor is an expert on childhood acute lymphoblast leukaemia.

Professor Vormoor is a children’s cancer doctor at the Great North Children’s Hospital specialising in childhood acute lymphoblastic leukaemia (ALL) and in our latest Expert Opinion interview, he and Dr Heidenreich talk about their plans to transform treatment for children with ALL. Continue reading

NCRI Cancer Conference – day one

NCRI banner

The NCRI Cancer Conference is in full swing

The NCRI conference began in earnest yesterday afternoon, with the presentation of a Cancer Research UK ‘lifetime achievement’ award to The Institute of Cancer Research’s Professor Chris Marshall.

Professor Marshall has been funded by Cancer Research UK and our predecessor, The Cancer Research Campaign, for around 30 years. He treated us to a selection of his ‘greatest hits’, focusing on his work in cell signalling – the molecular signals that ensure cells know when to multiply, die and move – and how this goes wrong in cancer.

Looking back over the past three decades, he highlighted how we’ve moved in a remarkably short time from knowing virtually nothing about the faulty genes and molecules that drive cancer to having a wealth of knowledge at our fingertips. Many of these molecules are involved in cell signalling, and there are a number of exciting potential drugs in the pipeline that target them.

Continue reading

ASCO 2011 – the challenge and promise of the genomic era

Cancer Research UK’s Senior Science Information Manager, Dr Julie Sharp, reports from this year’s US cancer conference

George W. Sledge, MD

Dr George Sledge, addressing the ASCO 2011 conference

Around 30,000 cancer doctors and researchers have gathered in Chicago for the annual American Society of Clinical Oncology (ASCO) conference. It’s an opportunity for cancer specialists to hear the very latest results from trials of new treatments, and learn more about hot topics such as personalised medicine or new DNA sequencing technologies.

In his welcome speech, outgoing ASCO president Dr George Sledge discussed the challenges ahead as we enter what he termed an ‘era of genomics’.

In the not-too-distant future, according to Dr Sledge, fast and cheap technologies will be used to map each patient’s genetic make-up, compare it with that of their cancer and highlight all the faults in their DNA that affect how their cancer responds to treatment.

While this information has the power to transform treatment for patients around the world, there are still huge challenges ahead for scientists and doctors. As the costs of analysing – or ‘sequencing’ – DNA plummet, doctors need to find ways to start translating this new genetic knowledge in a way that’s useful and beneficial for patients.

Continue reading

What does the future hold for cancer research? Find out in this month’s podcast

Cancer Research UK podcast logo

Click on the image to listen to the latest podcast

This month we’ve got an exclusive in-depth interview with Cancer Research UK’s chief clinician Professor Peter Johnson and our newly-appointed chief scientist, Professor Nic Jones.

They discuss the challenges that we face in cancer research over the coming years, how lab scientists and cancer doctors can work better together, the new technology that’s shaping our research, and whether we will ever pin down that elusive “cure for cancer”.

Listen now through the audio player below:

Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.

Or click here to download the podcast as an mp3.

Also, the podcast is available on iTunes to subscribe and download for free.

Alternatively, go to the podcast homepage, where you can hear the show directly through our own Flash player. And there’s also a full transcript of the podcast available here.

We hope you enjoy it – please do let us know what you think of the podcast in the comments below, or email us at podcast@cancer.org.uk.

Kat

Cancer stem cells – a promising avenue for cancer research

A micrograph of some dividing cells

Are rogue stem cells the root cause of cancer?

Cancer ‘stem cells‘ are a recurring topic on this blog. Many scientists think that these are the cells at the source of tumours, drive and renewing cancers yet resistant to treatment.

Last Saturday’s Guardian contained an excellent feature article by US cancer specialist Siddhartha Mukherjee, discussing what the future holds for cancer research. It’s quiet long but well worth reading.

Like many researchers, Mukherjee believes that one day we will eventually transform cancer into a long-term, manageable disease. As he writes:

In the past, cancer was typically imagined as an acute disease, treated with surgery, radiation and chemotherapy. And the trifecta of assaults led to only two possible outcomes. Either cancer was eradicated from the body – in other words “cured” – or it remained recalcitrant to treatment, and was “incurable”. The metaphors attached to cancer followed this binary outcome. Patients fought a ”battle” with cancer. If cancer was defeated, then patients “won” the war. If patients lost the battle, the cancer was victorious. There was no intermediate outcome – no truce.

But for many forms of cancer, this binary description no longer captures the truth. Take, for instance, a young woman with breast cancer. She may initially have surgery to remove the primary tumour from her breast. But we now know that surgical removal of the tumour may not cure such a patient outright. Microscopic deposits of cancer cells may be left behind after surgery that can be eradicated only with chemotherapy and radiation, typically administered over several months. And more drugs and treatments might follow. If her cancer is of a particular subtype, she may receive anti-oestrogen therapy for several years.

During this time, and for decades after, she may be tested with mammography to detect early breast cancer in her other breast. Her daughters may be tested for carrying genes that predispose to breast cancer. Indeed, her course of therapy might stretch into five or even 10 years, perhaps even to the next generation…. Cancer will become a chronic condition for her; [and] the combination of surgery, chemo and radiation will likely extend her survival… cancer will become the new “normal”.

A big part of this, according to Mukherjee, will involve understanding more about cancer stem cells: what they are, where they come from, and how they drive the disease.

In the mid-1990s, John Dick, a Canadian biologist working in Toronto, postulated that a small population of cells in human leukaemias also possess this infinite self-renewing behaviour. These “cancer stem cells” act as the persistent reservoir of cancer – generating and regenerating cancer infinitely. When chemotherapy kills the bulk of cancer cells, a small remnant population of these stem cells, thought to be intrinsically more resistant to death, regenerate and renew the cancer, thus precipitating the common relapses of cancer after chemotherapy.

Indeed, cancer stem cells have acquired the behaviour of normal stem cells by activating the same genes and pathways that make normal stem cells immortal – except, unlike normal stem cells, they cannot be lulled back into physiological sleep. Cancer, then, is quite literally trying to emulate a regenerating organ – or perhaps, more disturbingly, the regenerating organism. Its quest for immortality mirrors our own.

It’s now becoming clear that by understanding the nature and identity of these stem cells, we could – theoretically at least – put the brakes on them and stop the disease in its tracks.

Turning theory into practice is what we aim to do here at Cancer Research UK, and the exciting field of stem cell research is no exception. That’s why last week we announced that we’ve hand-picked a crack team of experts, already dubbed the ‘C-Team’,  to focus on cancer stem cell research.

We’re backing this team, more formally known as the Cancer Stem Cell Consortium, with £500,000 over two years, which they’ll be using to look for ways to spot cancer stem cells, monitor their activity, and target them with drugs.

We wish them every success in their quest.

Henry